Drug class
Vesicular monoamine transporter 2 (VMAT2) inhibitor; monoamine-depleting agent
Mechanism of action
Reversibly inhibits VMAT2, reducing uptake of monoamines into synaptic vesicles and thereby decreasing vesicular storage and release of dopamine and other monoamines. The precise contribution of individual monoamines to clinical effects is not fully established.
General use cases
- Treatment of chorea associated with Huntington disease
- Treatment of tardive dyskinesia in adults; dose and monitoring depend on product-specific CYP2D6 and safety requirements
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
